Selling Your Dental Practice UK 2026 Guide

The UK dental practice sale market entered 2026 with the strongest run of demand in a decade. According to Practice Plan's market commentary, 2025 saw one Manchester practice attract 37 viewings and 27 offers, with similar competitive dynamics across Liverpool, Cheshire and Lancashire. Sale prices that dipped 6.4% in 2023 according to Business Sale Report recovered through 2024 and 2025, and PE-backed groups like MyDentist, Portman Dentex, Rodericks Dental and Bupa Dental Services reported gross profits rising 20% year on year between 2023 and 2024 per a Mail on Sunday investigation.

If you own a UK dental practice and are within five years of an exit, the buyer landscape has never been more diverse or more aggressive. The decision is no longer whether to sell to a DSO - it is which DSO, on what terms, and with what level of clinical autonomy retained. Practice owners exploring options should start by understanding the three contractual fault lines that determine value: NHS exposure, associate dependency and lease quality. For UK-specific market commentary across the healthcare sector, see our dental M&A advisory page.

This guide covers practice valuation methodologies, current EBITDA multiples, the named UK DSO buyers, NHS contract transfer mechanics, the 2026 NHS reform impact, and the sale process owners should run to achieve maximum value.

How UK dental practices are valued in 2026

Three methodologies dominate UK dental practice valuation. Sophisticated buyers and advisers use all three and triangulate.

EBITDA multiple. The dominant method for practices generating more than £150k of normalised earnings. Per Eclipse Corporate Finance's 2025 valuation guide, UK dental EBITDA multiples typically range from 6.5x to 9.5x depending on practice profile, recurring revenue mix and growth profile. A £350k EBITDA practice at 7x = £2.45m enterprise value. Critical inputs: how EBITDA is normalised (owner add-backs, associate cost adjustments, working capital), whether the figure is "owner-operated" or "associate-led" (the same practice yields very different EBITDA depending on which basis is presented), and whether multiples are pre or post lease normalisation.

Goodwill percentage of turnover. Used for smaller, owner-operated practices and quick benchmarking. Mixed NHS/private practices in 2024-2025 typically traded at 90% to 130% of turnover, fully private practices at 110% to 160%, and NHS-only practices at 60% to 100% depending on contract value, UDA rate and area. The Business Sale Report London example shows a £780k turnover practice priced at £1.05m (135% of turnover) with £300k of NHS contract income - this is roughly market for that profile.

Discounted cash flow. Used by sophisticated DSO acquirers for larger practices and group transactions. DCF captures growth trajectory, NHS contract renewal risk, capital expenditure cycles and associate retention assumptions that single-period EBITDA multiples cannot. Most owners will not see this method applied in isolation but should expect it to underpin large DSO offers.

The owner-operated versus associate-led distinction matters enormously. Associate-led practices are those where the principal does not provide significant chair time, all dentist labour is in the P&L, and EBITDA reflects the true sustainable profit. Owner-operated practices add back the principal's notional dentist income and consequently show higher EBITDA but lower multiples - typically 4.5x to 6.5x versus 7x to 9.5x for associate-led practices of equivalent quality. This is not arbitrary. Buyers correctly recognise that owner-operated practices carry continuity risk once the principal exits.

Current EBITDA multiple ranges by practice type

The table below synthesises ranges from Eclipse Corporate Finance, FOCUS Investment Banking, Business Sale Report and DealFlowAgent transaction observations. Multiples assume clean financials, transferable lease, low associate turnover and no material NHS contract risk.

Multi-site groups and platform DSOs trade at the upper end because they are the assets PE sponsors target as platform acquisitions or accretive bolt-ons into existing portfolios. The Dentalcorp take-private completed in late 2025 illustrates the upper end of the global market: GTCR agreed to take Canada's Dentalcorp private in a C$2.2 billion all-cash deal worth approximately C$3.3 billion enterprise value, with the meeting to finalise the transaction scheduled for December 4, 2025.

For owners benchmarking their own practice value, FOCUS Investment Banking's 2026 valuation update cites a 5x to 8x add-on range for bolt-on dental practices acquired by US DSO platforms, with revenue multiples of approximately 1.0x to 1.8x. UK multiples for equivalent practices are broadly in line, with the regulated NHS contract element creating both downside (transfer complexity) and upside (recurring revenue stability) depending on the buyer's strategy. Our buy-side advisory team maintains transaction comparables for UK dental practices across each category.

The 2026 NHS contract reform and what it means for valuations

April 2026 brings the biggest overhaul of NHS dental contracts in two decades, and it directly affects how buyers price practice goodwill. LinkedIn commentary by industry observers summarises the key changes, with NHS England's contractual guidance the primary source.

Per Henry Schein's UDA reform analysis, the changes introduce higher payments for complex and high-needs patients through nationally set care packages, improved remuneration for denture work and preventive treatments, a mandated 8.2% allocation for unscheduled care with payments of £15 per slot (£75 if treated), funded peer review schemes and £213 annual appraisals, plus expanded NHS benefits eligibility including Dental Core Training time.

The valuation implications are mixed. Practices weighted to complex care and prevention should see UDA values rise modestly. Practices reliant on high volumes of simple routine treatment may see effective UDA values fall as the reform reallocates funding towards complex casework. Buyers in 2026 are stress-testing pre-reform UDA performance against the new banded payment structure before committing to multiples.

In parallel, the Competition and Markets Authority launched a review of private dentistry in early 2026 covering pricing transparency, complaints handling and ownership concentration. The review affects DSO acquisition strategy at the top end and pricing practices at the practice level. For owners selling in 2026, the CMA review is not a deal blocker but it is a diligence checkpoint - DSO buyers are documenting compliance with disclosure and complaints standards more rigorously than they did in 2024.

NHS contract transfer mechanics

The single most important practical issue in selling a mixed or NHS practice is how the GDS contract transfers to the buyer. Per Carter Bond Solicitors and PFM Dental, NHS dental contracts cannot be sold directly - they are held by the contract-holder and the buyer must either be incorporated into that contract or receive a novation via the local NHS Integrated Care Board.

The standard mechanisms. Most UK dental sales today complete via a share sale of the limited company that holds the contract (often after the principal has incorporated the contract into a limited company in advance of sale). For sole-trader contracts, the process involves the seller incorporating before sale and then selling shares, or in some cases adding the buyer as a partner before the seller resigns from the contract via a 24-month or 6-month partnership transfer route.

Why this matters for value. Buyers price NHS contract transfer risk explicitly. A contract held in a clean limited company structure with at least 12 months of trading history is worth meaningfully more than a sole-trader contract requiring incorporation as a condition of the sale. Owners should structure for sale 18 to 24 months in advance, ideally by incorporating the practice and running the contract through the limited company well before going to market.

Lead times. NHS England/ICB approval for contract changes typically takes 6 to 12 weeks. Completions are routinely scheduled 4 to 6 months after heads of terms to allow for NHS approval, CQC registration changes, lease assignment and finance. Owners who underestimate this timeline often pay carrying costs (locum coverage, retention bonuses for associates) that erode net sale proceeds.

The named UK DSO buyers in 2026

These are the corporate groups most likely to approach UK dental practice owners over the next 18 months.

Portman Dentex (Core Equity Holdings). UK and Ireland leader following the 2023 Dentex merger which delivered a 75% revenue uplift per The MBS Group. Continuing to acquire premium private and mixed practices via the Portman Dentex acquisition platform. Targets practices with strong private mix, good clinical reputation and growth potential.

MyDentist (Palamon Capital/funds). UK's largest dental group by site count, historically focused on NHS-weighted practices. Reduced acquisition pace in 2023-2024 but remains an active buyer in 2026, particularly for mid-sized mixed practices.

Rodericks Dental Partners. Mid-market consolidator active across England and Wales, acquiring associate-led mixed and private practices.

Bupa Dental Services. Insurer-backed group with a clear private and prevention focus, generally less acquisitive but selectively active.

Genesis Dental Care. PE-backed mid-market group focused on premium private and mixed practices.

Dental Partners. UK consolidator with active bolt-on programme.

Riverdale Healthcare. Active acquirer particularly in private and specialist practices.

Independent buyers and search funds. Single-practice and small group buyers (often dentist-led, sometimes backed by family offices or independent sponsors) compete at the £500k to £3m enterprise value range. They typically pay slightly lower multiples than corporate consolidators but offer faster completion, more flexibility on earn-outs and continuity of practice culture.

International entrants. US and European DSO platforms increasingly view the UK as a target market. With Dentalcorp's take-private demonstrating PE conviction at scale, US sponsors with UK ambitions are running scoping exercises throughout 2026. Owners running competitive processes in 2026 should expect at least one international participant in the buyer set for mid-market and larger transactions. The dynamic is broadly comparable to the parallel PE-led roll-up activity in UK care homes and veterinary practices, where consolidation has run for longer and produced multiple successful exits at scale.

What drives premium multiples

Six factors consistently separate top-quartile multiples from average ones in UK dental practice transactions.

Private mix above 50%. Practices with majority private income trade at 1.0x to 2.0x higher multiples than NHS-heavy equivalents. Private revenue is uncapped, more easily grown and not subject to UDA reform risk.

Associate stability. Long-tenured associates with restrictive covenants and clear handover plans materially reduce buyer risk. Practices with high associate turnover or principal-dependent revenue lose 1.0x to 2.0x of multiple.

Lease quality. A 10+ year lease with manageable rent reviews unlocks DSO buyers. Short leases (under 7 years) limit the buyer universe and depress multiples. Freehold or owned premises typically sit outside the EBITDA multiple as a separate property transaction.

CQC compliance and clinical governance. Recent CQC reports with no enforcement actions, documented clinical governance processes, and clean complaints histories support premium pricing. Any open CQC actions or pending complaints create direct value risk.

Growth trajectory. Practices showing 5%+ organic revenue growth over three years attract premium pricing. Buyers pay for trajectory, not just current EBITDA.

Specialist services and equipment. In-house implant capability, orthodontics, cosmetic procedures or recent CBCT/digital scanner investment justify premium multiples - particularly for buyers building specialist-led platforms.

The sale process owners should run

Selling at maximum value requires running a structured process, not waiting for inbound approaches.

Pre-sale preparation (12 to 24 months). Incorporate the practice and run NHS contract through the limited company. Normalise principal salary and remove non-business expenses. Document associate contracts with appropriate restrictive covenants. Refresh CQC registration. Address any complaints or clinical governance gaps. Refresh the lease if it is under 8 years remaining. Build a 36-month financial track record clearly evidencing run-rate EBITDA.

Adviser selection. Engage a specialist dental M&A adviser, not a generic small-business broker. The dental buyer universe is concentrated and the contractual mechanics (NHS contract, CQC, lease) require dental-specific experience. Advisers should be paid largely on success, with a clearly defined buyer outreach scope.

Information memorandum and buyer outreach. A professional IM covering financials, NHS contract details, clinical activity mix, associate composition and growth plan. Targeted outreach to the right 8 to 15 buyers (mix of corporates, mid-market consolidators and independents) rather than mass marketing.

Heads of terms and exclusivity. Multiple competing heads of terms drive the highest valuation. Owners should resist granting exclusivity until commercial terms (price, earn-out structure, lock-up, restrictive covenants) are agreed in detail.

Due diligence and SPA negotiation. Allow 8 to 14 weeks for diligence and share purchase agreement negotiation. Key negotiation points: NHS contract clauses, associate retention, working capital adjustment, completion accounts versus locked box, indemnities and warranties, restrictive covenants on the seller and key associates.

Completion. NHS England approval, CQC registration change, lease assignment, finance drawdown, completion meeting. Sellers should plan for at least 6 to 12 weeks between exchange (signed SPA) and completion to allow regulatory steps.

Earn-outs, deferred consideration and rollover

Headline price is rarely the cash at completion. Typical UK DSO deal structures in 2026 involve:

Cash at completion. 60% to 80% of headline price, paid on the day of completion subject to working capital and net debt adjustments.

Deferred consideration. 10% to 25% paid 12 to 36 months post-completion, contingent on EBITDA targets, associate retention or NHS contract continuity. Earn-out definition is the single most negotiated element of UK dental SPAs in 2026 - documenting precisely how EBITDA is calculated, what synergies are excluded and how disputed adjustments are handled often determines whether sellers receive 100% or 60% of the deferred amount.

Equity rollover. 5% to 20% in newco shares for larger transactions where the seller continues to operate the practice post-sale. Rollover allows sellers to participate in upside on the next exit but exposes them to platform-level performance and leverage.

Restrictive covenants. Typical 24 to 48 month non-compete and non-solicit covenants covering a defined geographic radius. Buyers price covenants explicitly - sellers seeking shorter restrictions usually accept lower headline value.

The single biggest source of post-completion disputes is earn-out interpretation. Owners should negotiate earn-out definitions with the same intensity as headline multiples - ideally with the assistance of an experienced dental M&A adviser and a transactional lawyer with dental sector experience.

Risks and what can go wrong

UK dental practice sales fail or underperform for predictable reasons.

NHS contract complications. Late discovery of contract-holder issues, partnership transfer requirements or ICB approval delays can collapse deals or extend timelines by months. Pre-sale incorporation and clean contract structure prevent the majority of these issues.

Associate flight. Key associates leaving during the diligence period or shortly after completion destroy value. Buyers protect against this through retention bonuses tied to the SPA and restrictive covenants in associate contracts. Sellers should engage associates appropriately well before going to market.

CQC issues. Open enforcement actions or recent inadequate ratings make practices effectively unsaleable to corporate buyers until resolved. Pre-sale CQC remediation is essential where issues exist.

Earn-out disputes. Poorly drafted earn-outs lead to 18 to 36 month disputes over EBITDA calculation, working capital and synergies. Detailed earn-out drafting at SPA stage prevents most disputes.

Wrong adviser or buyer. Generic brokers running undifferentiated processes typically deliver headline multiples 1.0x to 2.0x below specialist dental advisers running targeted processes to the right buyers.

Timing your exit

The 2026 market is favourable for sellers across most practice profiles. PE-backed DSOs are well-capitalised, NHS reform creates short-term uncertainty that motivates some owners to exit, and the post-Dentalcorp take-private wave is reinforcing international buyer interest. The risk is not finding a buyer - it is choosing the right one and structuring the deal correctly.

Most experienced dental advisers recommend a 24-month pre-sale runway. Owners 5+ years from exit should still focus on the value drivers above; the value uplift from clean structure, strong private mix and stable associates compounds over time. Owners within 24 months should be actively planning the process with a specialist adviser. Owners exploring adjacent healthcare exits can also see our medispas M&A overview for parallel commentary on the aesthetic and elective treatment market.

DealFlowAgent works with UK dental practice owners considering sale to corporate DSOs, mid-market groups or independent buyers. We map the buyer universe, run competitive processes and negotiate SPAs that protect headline value. If you are within 36 months of an exit, the time to start planning is now. Get in touch with our advisory team for a confidential discussion of your options.

Your Advisory Team

Experienced Dealmakers Lead Your Exit

Every exit is led by a senior advisor who has been through it themselves. Meet the team who will guide you.

Joe Lewin

Founder & Lead Advisor — M&A Specialist

• •4 years in M&A advisory; 22 completed transactions
• •Direct relationships with hundreds of strategic and financial acquirers
• •Raised £2m in funding; placed 3rd of 1,900 at OnStage (the "Y Combinator of Europe")
• •Previously built a mobility and field services business to 30 staff and 6 UK warehouses, then sold via competitive process with an EY M&A partner
• •Full-stack developer of advanced agent systems and second-brain tooling for the M&A process

Joe Thomason

Senior M&A Advisor

• •Previously Analyst at KBS Corporate
• •Analyst at Hampleton Partners, Associate at Tech Credit Partners
• •Worked on 25+ completed transactions (£300k to £120m)
• •Specialist in debt lending for business buyers

Emerson Patton

Sector Specialist: Building, Construction & Trade Services

• •20+ years advising owners in building services, fire safety, HVAC, plumbing, and construction
• •Guided 200+ companies through growth, profit improvement, and exit planning
• •Builds equity value and operational structure long before a sale
• •Partners with DFA to prepare owners for exit while the advisory team runs the sale

Sam Pouyan

Senior M&A Advisor

• •10 years across buy-side and sell-side M&A
• •Former investment banking analyst
• •Expert in financial modelling and deal structuring

James Duboullay

Senior M&A Advisor

• •25+ years across investment banking, M&A and fundraising
• •Sector focus: essential services and software
• •Long-standing relationships with private equity buyers and growth funds
• •Personally advising DealFlowAgent founders for the past four years

Sage

AI Deal Concierge

• •Available 24/7. Monitors every signal in your deal
• •Keeps your advisory team one step ahead at all times
• •Trained on thousands of M&A transactions

Sterling

Buy-Side Deal Origination Agent

• •Engages 12,000+ acquirers to surface live mandates and intent
• •Qualifies buyer fit, budget and timing before introductions
• •Feeds your advisory team with warm, ranked buyer matches

Tim Armoo

Partner & Chief Marketing Officer

• •Founded Fanbytes, scaled revenues to £10m+, exited at multi-eight-figure valuation
• •Advises on multiple M&A deals, invests in early-stage ventures
• •Built 700,000+ follower community teaching founders to scale and sell
• •Partnered with DealFlowAgent to expand access for founders to buyers

Assigned Per Deal

Sector Expert

Industry-Specific M&A Advisor

For every deal, our advisory team includes a sector specialist from that client's specific industry and niche: bringing relationships, insider knowledge, and leverage to support your process and achieve the best acquisition outcome.

INTERVIEWING

Head of M&A

Senior hire — interviewing now

Final-round interviews underway with 100+ applicants. Joining May 2026 to lead the advisory bench across Building Services and Healthcare.

OFFER STAGE

Senior M&A Advisor

New seat — 100+ applicants

Sourced from boutique investment banks and Big-4 corporate finance teams. Joining May–June 2026.

INTERVIEWING

Senior M&A Advisor

Second seat — interviewing

Sector-specialist hire focused on the lower-mid market (£1M–£10M EBITDA). Joining May–June 2026.

We're actively expanding the bench — three senior M&A hires confirmed for May–June 2026. See open roles → Apply now →

Dental Practices M&A Specialists

Thinking of selling your dental practices business?

DealFlowAgent is the UK and US's only M&A advisory firm specialising in dental practice businesses. Our trusted advisors leverage industry knowledge, buyer relationships and proprietary technology to help business owners secure multiple acquisition offers at higher valuations.

Talk to a Real Advisor - No Obligation

Speak with Joe or Sam about your situation. No hard sell, no commitment, just honest advice from advisors who've been through it.

What's Your Business Actually Worth?

Our valuation tool gives you a realistic range based on recent comparable transactions in your sector. Takes 3 minutes.

Related Articles